Metabolism of dynorphin A(1-13)

Pharmazie

Volumn 59, Issue 5, 2004, Pages 339-343

  Brugos, B ^a   Hochhaus, Guenthr ^a,b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b Department of Pharmaceutical Sciences and Experimental Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYNORPHIN[1-13]; MORPHINE; OPIATE PEPTIDE; TYROSINE;

AMIDATION; CARBOXY TERMINAL SEQUENCE; CEREBROSPINAL FLUID; CHEMICAL MODIFICATION; CONFERENCE PAPER; DRUG METABOLISM; DRUG POTENTIATION; DRUG WITHDRAWAL; HUMAN; METHYLATION; NONHUMAN; PLASMA; STRUCTURE ACTIVITY RELATION;

ANIMALS; BLOOD-BRAIN BARRIER; DYNORPHINS; HUMANS; PEPTIDE FRAGMENTS;

EID: 2642535340     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (52)

1. Aceto MD, Dewey WL, Chang JK, Lee NM (1982) Dynorphin (1-13) effects in nontolerant and morphine-dependent rhesus monkeys. Eur J Pharmacol 83: 139-142.
2. Banks WA, Kastin AJ, Fischman AJ, Coy DH, Strauss SL (1986) Carrier-mediated transport of enkephalins and N-tyr-MIF-1 across blood-brain barrier. Am J Physiol 251: E477-E482.
3. Borlongan CV, Emerich DF (2003) Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. Brain Res Bull 60: 297-306.
4. Brinckerhoff L, Kalashnikov V, Thompson L, Yamshchikov G, Pierce R, Galavotti H, Engelhard V, Slingluff CJ (1999) Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int J Cancer 83: 326-334.
5. Caudle RM, Isaac L (1987) Intratechal dynorphin (1-13) results in irreversible loss of tail flick reflex in rats. Brain Res 435: 1-6.
6. Chavkin C, Goldstein A (1981) Specific receptor for the opioid peptide dynorphin: structure-activity relationships. Proc Natl Acad Sci 78: 6543-6547.
7. Chavkin C, James IF, Goldstein A (1982) Dynorphin is a specific endogenous ligand of the x receptor. Science 215: 413-415.
8. Chen L, Gu Y, Huang LYM (1995) The opioid peptide dynorphin directly blocks NMDA receptor channels in the rat. J Physiol 482: 575-581.
9. Chou JZ, Chait BT, Wang R, Kreek MJ (1996) Differential biotransformation of dynorphin A(1-17) and dynorphin A(1-13) peptides in human blood, ex vivo. Peptides 17: 983-990.
10. Csuhai E, Little SS, Hersh LB (1995) Inactivation of neuropeptides. Prog Brain Res 104: 131-141.
11. Friedman HJ, Jen MF, Chang JK, Lee NM, Loh HH (1981) Dynorphin: a possible modulatory peptide on morphine or β-endorphin analgesia in mouse. Eur J Pharmacol 69: 351-360.
12. Gambus PD, Schnider TW, Minto CF, Youngs EJ, Billard V, Brose WG, Hochhaus G, Shafer SL (1998) Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naive and opioid-treated human volunteers. Clin Pharmacol Ther 64: 27-38.
13. Goldstein A, Tachibana S, Lowney LI, M. H, L. H (1979) Dynorphin-(1-13), an extraordinary potent opioid peptide. Proc Natl Acad Sci 76: 6666-6670.
14. Green PG, Lee NM (1988) Dynorphin A-(1-13) attenuates withdrawal in morphine-dependent rats: effect of route of administration. Eur J Pharmacol 145: 267-272.
15. Hauser KF, Foldes JK, Turbek ST (1999) Dynorphin A(1-13) neurotoxicity in vitro: Opioid and non-opioid mechanisms in mouse spinal cord neurons. Exp Neurol 160: 361-375.
16. Heavner G, Kroon D, Audhya T, Goldstein G (1986) Biologically active analogs of thymopentin with enhanced enzymatic stability. Peptides 7: 1015-1019.
17. Herman BH, Goldstein A (1985) Antinociception and paralysis induced by intratechal dynorphin-A. J Pharmacol Exp Ther 232: 27-32.
18. 2, in mice. Br J Pharmacol 132: 1948-1956.
19. Hooke LP, Lee NM (1995) Dynorphin A modulates acute and chronic opioid effects. J Pharmacol Exp Ther 273: 292-297.
20. 1] Dynorphin A-(2-17) has naloxone-insensitive antinociceptive effect in the writhing assay. J Pharmacol Exp Ther 273: 802-807.
21. Hu J, El-Fakahany EE (1993) Allosteric interaction of dynorphin and myelin basic protein with muscarinic receptors. Pharmacol 47: 351-359.
22. Laughlin TM, Larson AA, Wilcox GL (2001) Mechanisms of induction of persistent nociception by dynorphin. J Pharmacol Exp Ther 299: 6-11.
23. Leslie FM, Goldstein A (1982) Degradation of dynorphin A1-13 by membrane-bound rat brain enzymes. Neuropep 2: 185-196.
24. McCleave MJ, Elliott RJ, Archbold GP (1996) Human plasma carboxypeptidases N; stability of enzyme activity following collection. Biochem Soc Trans 24: 42S.
25. Muller S, Hochhaus G (1995) Metabolism of dynorphin A1-13 in human blood and plasma. Pharm Res 12: 1165-1170.
26. Muller S, Grundy BL, Hochhaus G (1996) Metabolism of dynorphin A1-13 in human CSF. Neurochem Res 21: 1213-1219.
27. 3H]-L-glutamate in rat brain membranes by metabolic dynorphin fragments. Pharmazie 53: 142-143.
28. Muller S, Ho B, Gambus P, Millard W, Hochhaus G (1997) An HPLC/ RIA method for dynorphin A1-13 and its main metabolites in human blood. J Pharm Biomed Anal 16: 101-109.
29. Nakazawa T, Ikeda M, Kaneko T, Yamatsu K (1985) Analgesic effects of dynorphin-A and morphine in mice. Peptides 6: 75-78.
30. Nyberg F, Lyrenas S, Terenius L (1986) Assay and biochemical characterization of a dynorphin converting enzyme in human cerebrospinal fluid. NIDA Res Monogr 75: 251-254.
31. Pentel PR, Wananukul W, Hooke LP, Jones CRN, Hatsukami D, Anderson WR, Lee NM (1995) Effects of high intravenous doses of dynorphin A(1-13) on tail flick latency and central nervous system histology in rats. Pharmacol Biochem Behav 51: 387-390.
32. Persson S, Post C, Alari L, Nyberg F, Terenius L (1989) Increased neuropeptide-converting enzyme activities in cerebrospinal fluid of opiate-tolerant rats. Neurosc. Lett 107: 318-322.
33. Powell MF, Grey H, Gaeta F, Sette A, Colon S (1992) Peptide stability in drug development: a comparison of peptide reactivity in different biological media. J Pharm Sci 81: 731-738.
34. Przewlocki R, Przewlocka B (2001) Opioids in chronic pain. Eur J Pharmacol 429: 79-91.
35. Quillan JM, Sadee W (1997) Dynorphin peptides: antagonists of melanocortin receptors. Pharm Res 14: 713-719.
36. Safavi A, Hersh LB (1995) Degradation of dynorphin-related peptides by the puromycin-sensitive aminopeptidase and aminopeptidase M. J Neurochem 65: 389-395.
37. Shukla VK, Lemaire S (1994) Non-opioid effects of dynorphins: possible role of the NMDA receptor. Trends Pharmacol Sci 15: 420-424.
38. Smith AP, Lee NM (1988) Pharmacology of dynorphin. Ann Rev Pharmacol Toxicol 28: 123-140.
39. Specker S, Wananukul W, Hatsukami D, Nolin K, Hooke L, Kreek MJ, Pentel PR (1998) Effects of dynorphin A(1-13) on opiate withdrawal in humans. Psychopharmacology 137: 326-332.
40. Takemori AE, Loh HH, Lee NM (1992) Suppression by dynorphin A-(1-13) of the expression of opiate withdrawal and tolerance in mice. Eur J Pharmacol 221: 223-226.
41. Terasaki T, Hirai K, Sato H, Kang YS, Tsuji A (1989) Absorptive-mediated endocytosis of a dynorphin-like analgesic peptide, E-2078, into the blood-brain barrier. J Pharmacol Exp Ther 251: 351-357.
42. Terenius L, Nyberg F (1988) Neuropeptide-processing, -converting, and -inactivating enzymes in human cerebrospinal fluid. Int Rev Neurobiol 30: 101-121.
43. Turner TD, Browning JL, Widmayer MA, Baskin DS (1998) Penetration of dynorphin 1-13 across the blood-brain barrier. Neuropeptides 32: 141-149
44. Vanderah TW, Ossipov MH, Lai J, Malan TP, Porreca F (2001) Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin. Pain 92: 5-9.
45. 1-13 in the mouse and rat: initial observations. Peptides 1: 341-345.
46. Wen HL, Ho WKK (1982) Suppression of withdrawal symptoms by dynorphin in heroin addicts. Eur J Pharmacol 82: 183-186.
47. Wen HL, Ho WKK, Wen PYC (1984) Comparison of the effectiveness of different opioid peptides in suppressing heroin withdrawal. Eur J Pharmacol 100: 155-162.
48. Wettergren A, Pridal L, Wojdemann M, Holst J (1998) Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans. Regul Pept 77: 83-87.
49. Yoshino H, Nakazawa T, Arakawa Y, Kaneko T, Tsuchiya Y, Matsunaga M, Araki S, Ikeda M, Yamatsu M, Tachibana S (1990) Synthesis and structure-activity relationships of dynorphin A(1-8) amide. J Med Chem 33: 206-212.
50. Young EA, Walker M, Houghten R, Akli H (1987) The degradation of dynorphin A in brain tissue in vivo and in vitro. Peptides 8: 701-707.
51. Yu J, Butelman ER, Woods JH, Chait BT, Kreek MJ (1997) Dynorphin A(1-8) analog, E-2078, is stable in human and rhesus monkey blood. J Pharmacol Exp Ther 280: 1147-1151.
52. Zhang S, Yu L (1995) Identification of dynorphins as endogenous ligands for an opioid receptor-like orphan receptor. J Biol Chem 270: 22772-22776.